Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs GraniteShares 2x Long COIN Daily ETF (CONL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs GraniteShares 2x Long COIN Daily ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while GraniteShares 2x Long COIN Daily ETF trades at $4.85. Which is the better fit depends on your goals.
| ALNY | CONL | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $491.22 | $64.57 |
52-Week Low | $278.09 | $4.09 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
CONL, the GraniteShares 2x Long COIN Daily ETF, trades at $4.95 with a slight 0.61% daily gain. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators remain neutral. The ETF has experienced significant volatility, losing 67% year-to-date according to 24/7 Wall Street (June 6, 2026), reflecting the amplified risks of daily-reset leverage on Coinbase stock performance.
The outlook remains highly speculative with potential for explosive gains if Bitcoin rallies toward $100,000, but investors face substantial volatility decay risks. Recent cryptocurrency momentum provides short-term catalysts, though the leveraged structure makes CONL suitable only for sophisticated traders comfortable with rapid capital erosion during market whipsaws.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About GraniteShares 2x Long COIN Daily ETF
CONL is a leveraged ETF that seeks to provide two times (2x) the daily performance of Coinbase Global (COIN) stock. It is designed for investors seeking magnified short-term exposure to the price movements of Coinbase.
Read more on CONL →
